In-treatment stroke volume predicts cardiovascular risk in hypertension
Authors:
- Mai T. LønnebakkenMLMai T. Lønnebakken
- Eva GerdtsEGEva Gerdts
- Kurt BomanKBKurt Boman
- Kristian WachtellKWKristian Wachtell
- Björn DahlöfBDBjörn Dahlöf
- Richard B. DevereuxRDRichard B. Devereux
- 1 August 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29 (8) , 1508-1514
Abstract
To evaluate whether lower stroke volume during antihypertensive treatment is a predictor of cardiovascular events independent of left ventricular geometric pattern. The association between left ventricular stroke volume and combined cardiovascular death, stroke and myocardial infarction, the prespecified primary study endpoint, was assessed in Cox regression analysis using data from baseline and annual follow-up visits in 855 patients during 4.8 years of randomized losartan-based or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. During follow-up, a total of 91 primary endpoints occurred. At baseline, lower left ventricular stroke volume was associated with smaller body size, female sex, lower left ventricular mass and stress-corrected midwall shortening, higher relative wall thickness and total peripheral resistance, more concentric left ventricular geometry and impaired diastolic relaxation (all P < 0.01). Baseline stroke volume did not predict outcome. However, in time-varying multivariable Cox regression analysis, lower in-treatment left ventricular stroke volume indexed for height was associated with higher risk of cardiovascular events {hazard ratio 1.69 per 1 SD (6 ml/m) lower stroke volume [95% confidence interval (CI) 1.35-2.11], P < 0.001} independent of in-treatment left ventricular mass and concentric geometry and in a secondary model also independent of stress-corrected midwall shortening, impaired diastolic relaxation, heart rate, new-onset atrial fibrillation and study treatment [hazard ratio 1.46 per 1 SD (6 ml/m) lower stroke volume (95% CI 1.13-1.88)]. Assessment of in-treatment left ventricular stroke volume may reflect cardiac and vascular remodeling and impairment and, hence, adds information on cardiovascular risk in treated hypertensive patients beyond assessment of left ventricular structure alone. NCT 00338260.Keywords
This publication has 30 references indexed in Scilit:
- Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)European Heart Journal - Cardiovascular Imaging, 2008
- 2007 Guidelines for the Management of Arterial HypertensionJournal Of Hypertension, 2007
- Prognostic Significance of Left Ventricular Mass Change During Treatment of HypertensionJAMA, 2004
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 2002
- Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: The LIFE StudyJournal Of Hypertension, 2001
- Reliability of echocardiographic assessment of left ventricular structure and functionJACC, 1999
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- H35 Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension studyAmerican Journal of Hypertension, 1997
- Relation of Left Ventricular Mass and Geometry to Morbidity and Mortality in Uncomplicated Essential HypertensionAnnals of Internal Medicine, 1991
- Reproducibility of cardiac stroke volume estimated by doppler echocardiographyThe American Journal of Cardiology, 1987